Aeluma, Inc. Form 8-K Summary
Business Context and Reporting Period
Aeluma, Inc. filed a Current Report on Form 8-K dated December 22, 2022, reporting a private equity financing and related registration rights and placement-agent arrangements. The filing does not provide quarterly or annual operating results.
Financing and Key Financial Metrics
- Shares issued: 517,000 shares of common stock.
- Purchase price: $3.00 per share.
- Gross proceeds: $1,551,000.
- Placement-agent cash fee: $101,030, plus certain reimbursable expenses.
- Placement-agent warrants: Warrants to purchase up to 29,067 shares at an exercise price of $3.00 per share.
- The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, cash balances, or liquidity after the offering.
Material Changes and Transaction Terms
The offering was completed with 21 accredited investors under subscription agreements. The Company agreed to register the shares sold in the offering, together with shares underlying the placement-agent warrants, pursuant to a Registration Rights Agreement.
The Company may conduct additional closings, but there is no guarantee that it will receive any additional proceeds. The transaction increases common shares outstanding and may result in future dilution if the placement-agent warrants are exercised.
Outlook, Risks, and Unusual Items
- The securities were sold in an unregistered offering in reliance on Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D.
- The shares and warrant shares may not be offered or sold in the United States absent registration or an applicable exemption.
- Registration of the securities does not guarantee that the Company will receive additional capital or that investors will be able to sell the shares.
- The filing provides no specific guidance, operating outlook, use-of-proceeds detail, or management forecast.
Investor Verification Items
- Verify the final number of shares issued and whether any additional offering closings occurred.
- Review the Subscription Agreement, Registration Rights Agreement, and placement-agent warrant terms filed as exhibits.
- Assess the impact of the 517,000-share issuance and potential exercise of 29,067 warrants on dilution.
- Confirm the Company’s post-financing cash balance, liquidity needs, and use of proceeds in subsequent filings.
- Review the Company’s later periodic reports for registration effectiveness, warrant activity, and operating performance.